Science

Zantrene® (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a high dose, less cardiotoxic chemotherapeutic. The recent identification that Zantrane® is an highly potent FTO inhibitor has driven intense scientific and clinical interest in Zantrene as a rapidly translatable pharmaceutical able to target the m6A RNA methylation pathway. History of Zantrene® Zantrene was originally developed by Lederle Laboratories in the 1970s as a lower cardiotoxic alternative to the anthracycline chemotherapeutics. Lederle trialled Zantrene on…

Latest News

+

22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed an agreement with The Sheba…

Race Oncology's Mr Phil Lynch (CEO & MD) and Dr Daniel Tillett (CSO & ED) presented to the MST Access…

Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in…